Literature DB >> 24014826

Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.

Nazha Hamdani1, Constantijn Franssen, André Lourenço, Inês Falcão-Pires, Dulce Fontoura, Sara Leite, Luisa Plettig, Begoña López, Coen A Ottenheijm, Peter Moritz Becher, Arantxa González, Carsten Tschöpe, Javier Díez, Wolfgang A Linke, Adelino F Leite-Moreira, Walter J Paulus.   

Abstract

BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction. They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification. The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks. METHODS AND
RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization. Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined. Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned. At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic. Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD. The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation. The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.
CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span. Titin hypophosphorylation importantly contributed to the underlying myocardial DD.

Entities:  

Keywords:  diabetes mellitus; diastole; heart failure; myocardium; obesity

Mesh:

Substances:

Year:  2013        PMID: 24014826     DOI: 10.1161/CIRCHEARTFAILURE.113.000539

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  109 in total

1.  Adenosine kinase inhibition enhances microvascular dilator function and improves left ventricle diastolic dysfunction.

Authors:  Alec Davila; Yanna Tian; Istvan Czikora; Amanda S Weissman; Nicholas Weinand; Guangkuo Dong; Jiean Xu; Jie Li; Huabo Su; Gaston Kapuku; Yuqing Huo; Zsolt Bagi
Journal:  Microcirculation       Date:  2020-05-25       Impact factor: 2.628

Review 2.  Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.

Authors:  Claudia Penna; Ioanna Andreadou; Manuela Aragno; Christophe Beauloye; Luc Bertrand; Antigone Lazou; Ines Falcão-Pires; Robert Bell; Coert J Zuurbier; Pasquale Pagliaro; Derek J Hausenloy
Journal:  Br J Pharmacol       Date:  2020-03-09       Impact factor: 8.739

Review 3.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 4.  The Type 2 Diabetic Heart: Its Role in Exercise Intolerance and the Challenge to Find Effective Exercise Interventions.

Authors:  J Chris Baldi; Genevieve A Wilson; Luke C Wilson; Gerard T Wilkins; Regis R Lamberts
Journal:  Sports Med       Date:  2016-11       Impact factor: 11.136

5.  A change of heart: oxidative stress in governing muscle function?

Authors:  Martin Breitkreuz; Nazha Hamdani
Journal:  Biophys Rev       Date:  2015-06-27

6.  A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II.

Authors:  Jessica A Regan; Adolfo Gabriele Mauro; Salvatore Carbone; Carlo Marchetti; Rabia Gill; Eleonora Mezzaroma; Juan Valle Raleigh; Fadi N Salloum; Benjamin W Van Tassell; Antonio Abbate; Stefano Toldo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-07-17       Impact factor: 4.733

7.  Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin.

Authors:  Michael R Zile; Catalin F Baicu; John S Ikonomidis; Robert E Stroud; Paul J Nietert; Amy D Bradshaw; Rebecca Slater; Bradley M Palmer; Peter Van Buren; Markus Meyer; Margaret M Redfield; David A Bull; Henk L Granzier; Martin M LeWinter
Journal:  Circulation       Date:  2015-01-30       Impact factor: 29.690

Review 8.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.

Authors:  Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser
Journal:  Eur Heart J       Date:  2018-08-01       Impact factor: 29.983

9.  Post-weaning high-fat diet accelerates kidney injury, but not hypertension programmed by maternal diabetes.

Authors:  Yessoufou Aliou; Min-Chun Liao; Xin-Ping Zhao; Shiao-Ying Chang; Isabelle Chenier; Julie R Ingelfinger; Shao-Ling Zhang
Journal:  Pediatr Res       Date:  2015-11-16       Impact factor: 3.756

10.  Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats.

Authors:  Camilo Toledo; David C Andrade; Claudia Lucero; Alexis Arce-Alvarez; Hugo S Díaz; Valentín Aliaga; Harold D Schultz; Noah J Marcus; Mónica Manríquez; Marcelo Faúndez; Rodrigo Del Rio
Journal:  J Physiol       Date:  2017-03-19       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.